Sclerosis multiplex (SM): vizsgálatok itt: Bosznia-Hercegovina

1 trial · From ClinicalTrials.gov, checked 2026. november 13.. Ask the study team whether a trial fits you.

• 2. fázisTaking people
  A Study to Evaluate Pharmacokinetics (PK) and Safety of Subcutaneous (SC) Ublituximab Administered at Various Injection Sites and Relative Bioavailability Via Autoinjector (AI) Versus Syringe Subcutaneously in Participants With Multiple Sclerosis (MS)

  Where

  Bihać, Mostar, Sarajevo, Tuzla, Zenica

  Életkor

  18 év to 65 év

  People

  350 worldwide

  Run by

  TG Therapeutics, Inc.

  See details and how to joinNCT07503873 · EU 2025-523757-33-00